Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
short-chain galactooligosaccharides + long-chain fructooligosaccharides
- Development stage
- Unknown
- Lead developer
- Danone
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A specific prebiotic combination of short-chain galactooligosaccharides (scGOS) and long-chain fructooligosaccharides (lcFOS), typically in a 9:1 ratio, designed to mimic the functional properties of human milk oligosaccharides. This mixture is used primarily as a supplement in infant formulas to promote gastrointestinal health and modulate immune responses. Clinical studies have shown that supplementation with this combination can improve stool consistency and frequency, support beneficial gut microbiota colonization (notably bifidobacteria), reduce the risk of constipation, and induce a beneficial immunoglobulin profile by reducing total IgE and certain IgG subclasses without affecting vaccine responses. The product is well tolerated in infants and toddlers[1][2][5].
- Brand names
- IMMUNOFORTIS
- Other names
- scGOS/lcFOSGOS/FOSshort-chain galacto-oligosaccharides and long-chain fructo-oligosaccharidesscGOS:lcFOS (9:1)
Beyond the preview
Go deeper on short-chain galactooligosaccharides + long-chain fructooligosaccharides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on short-chain galactooligosaccharides + long-chain fructooligosaccharides.